Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$37.71 USD

37.71
2,676,726

+0.25 (0.67%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $37.72 +0.01 (0.03%) 7:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

United Therapeutics (UTHR) Collaborates With Corsair Pharma

by Zacks Equity Research

United Therapeutics (UTHR) entered into an exclusive license agreement with Corsair Pharma.

    Zacks Equity Research

    Pfizer (PFE) Collaborates With Sangamo for Gene Therapy

    by Zacks Equity Research

    Pfizer entered into collaboration agreements with Sangamo Therapeutics and private biotech, Arvinas.

      Zacks Equity Research

      Inovio Amends Chinese Deal for Immunotherapy, Shares Up

      by Zacks Equity Research

      Inovio (INO) entered into an amended agreement with ApolloBio Corporation and grants ApolloBio the exclusive right to develop and commercialize VGX-3100 within Greater China.

        Zacks Equity Research

        Valeant (VRX) to Settle Allergan Litigation for $290 Million

        by Zacks Equity Research

        Valeant (VRX) and Pershing Square decided to resolve the claims of the long standing Allergan lawsuit for $290 million. Valeant will now pay 33% of the costs, down from the previous agreement of 60%.

          Zacks Equity Research

          Will Exelixis (EXEL) be Able to Carry '17 Momentum in 2018?

          by Zacks Equity Research

          Exelixis (EXEL) had a phenomenal run in 2017 driven by sales of Cabometyx and we expect the momentum to continue in 2018 on the back of the label expansion of the drug.

            Zacks Equity Research

            Exelixis' Cabometyx Gets FDA Nod for First-Line Kidney Cancer

            by Zacks Equity Research

            Exelixis (EXEL) received a significant boost with the approval of label expansion of lead drug Cabometyx for first-line kidney cancer.

              Zacks Equity Research

              Endo (ENDP) Earnings & Revenues Beat in Q3, Generics Weak

              by Zacks Equity Research

              Endo (ENDP) announced better-than-expected results for the third quarter. However, weakness in the generics segment persist and will impact results.

                Zacks Equity Research

                Perrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares Up

                by Zacks Equity Research

                Perrigo (PRGO) posts better-than-expected earnings with revenues also beating estimates. The company ups its guidance, courtesy of a continued positive execution across all business segments.

                  Zacks Equity Research

                  Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up

                  by Zacks Equity Research

                  Merrimack (MACK) reported narrower-than-expected loss in the third quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.

                    Zacks Equity Research

                    Pacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates

                    by Zacks Equity Research

                    Pacira's (PCRX) earnings surpassed estimates but sales missed the same in the third quarter of 2017. The company remains focused on the label expansion of Exparel.

                      Zacks Equity Research

                      Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3

                      by Zacks Equity Research

                      Catalyst Pharma (CPRX) remains focused on the development of its pipeline candidate firdapse in the third quarter of 2017.

                        Zacks Equity Research

                        VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down

                        by Zacks Equity Research

                        VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.

                          Zacks Equity Research

                          Aerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus

                          by Zacks Equity Research

                          Increased operating expenses mar Aerie's (AERI) Q3 performance.

                            Zacks Equity Research

                            Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut

                            by Zacks Equity Research

                            Jazz Pharmaceuticals (JAZZ) earnings beat estimates while revenues miss the same in Q3. The company also cuts its guidance due to lower-than-expected sales from Xyrem.

                              Zacks Equity Research

                              Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up

                              by Zacks Equity Research

                              Regeneron reported impressive results in the third quarter driven by strong performance of Eylea.

                                Zacks Equity Research

                                Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag

                                by Zacks Equity Research

                                Agenus (AGEN) incurred in line loss but sales missed estimates in the third quarter of 2017.

                                  Zacks Equity Research

                                  Infinity (INFI) Q3 Loss Narrower than Expected, View Intact

                                  by Zacks Equity Research

                                  Infinity Pharmaceuticals (INFI) Q3 loss was narrower than estimates and the year-ago quarter loss.

                                    Zacks Equity Research

                                    AVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda

                                    by Zacks Equity Research

                                    AVEO Pharmaceuticals reported narrower-than-expected adjusted loss in the third quarter. Moreover, it received approval for its first drug, Fotivda, which was approved in EU for bladder cancer.

                                      Zacks Equity Research

                                      Arena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat

                                      by Zacks Equity Research

                                      Arena Pharmaceuticals (ARNA) reports another quarter of lackluster Belviq sales. However, the company is likely to advance ralinepag in phase III study based on positive data from the previous stage.

                                        Zacks Equity Research

                                        Spectrum (SPPI) Earnings, Sales Beat Q3 Estimates

                                        by Zacks Equity Research

                                        Spectrum (SPPI) reports narrower-than-expected loss in Q3. Shares up.

                                          Zacks Equity Research

                                          Achillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus

                                          by Zacks Equity Research

                                          Achillion Pharmaceuticals' (ACHN) third-quarter loss was narrower than estimates. The company is focusing on expanding its key pipeline candidate in several indications.

                                            Zacks Equity Research

                                            Radius Health (RDUS) Earnings Miss in Q3, Tymlos in Focus

                                            by Zacks Equity Research

                                            Radius Health (RDUS) reported a wider-than-expected loss in third-quarter as expenses grew significantly for the commercialization of Tymlos.

                                              Zacks Equity Research

                                              Agios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y

                                              by Zacks Equity Research

                                              Agios (AGIO) reports narrower-than-expected loss with revenues marginally beating estimates. The top line also improves year over year, thanks to reimbursement received from Celgene.

                                                Zacks Equity Research

                                                Zoetis (ZTS) Beats on Q3 Earnings & Sales, Ups 2017 View

                                                by Zacks Equity Research

                                                Zoetis (ZTS) reported impressive third-quarter results beating estimates on both counts. Revenues were driven by strong demand for companion animal products worldwide.

                                                  Zacks Equity Research

                                                  Geron (GERN) Q3 Loss Narrower Than Expected, Sales Miss

                                                  by Zacks Equity Research

                                                  Geron's (GERN) loss per share in the third quarter was narrower than expected. However, revenues missed estimates. Imetelstat remains in focus.